Acquisition Pending
Merck KGaA acquisition of Bio-Techne
US$11bn enterprise value
Announced 25 Jun 2026 · NASDAQ: TECH · US$73.00 cash per share
Advisers
Bio-Techne
Target
- Financial adviser
- Legal adviser
- Communications
- Fairness opinion
Merck KGaA
Acquirer
- Financial adviser
- Legal adviser
- Target
- Bio-Techne
- Acquirer
- Merck KGaA
- Target based in
- United States
- Buyer based in
- Germany
- Sector
- Life Sciences
- Tags
- Life Sciences, Diagnostics
In the league tables
Similar deals
- Waters acquisition of BD Biosciences & Diagnostic Solutions business Jul 2025 · US$19bn · Life Sciences
- Tempus AI acquisition of Personalis Jul 2026 · US$1.9bn · Diagnostics
- Astorg acquisition of Thermo Fisher Scientific's microbiology division Apr 2026 · US$1.1bn · Diagnostics
- Agilent Technologies acquisition of Biocare Medical Mar 2026 · US$950m · Diagnostics
- Perceptive Capital Solutions Corp and Freenome Holdings merger Dec 2025 · US$725m · Diagnostics
Sources
- Jun 2026 Guggenheim Securities: Financial Advisor to Merck KGaA on its Acquisition of Bio-Techne guggenheimsecurities.com
- 25 Jun 2026 Press release (EX-99.1, exhibit), BIO-TECHNE CORPORATION 8-K sec.gov
- 25 Jun 2026 S&C Advises Merck KGaA on $11.3 Billion Acquisition of Bio-Techne sullcrom.com
- 25 Jun 2026 Sidley Represents Bio-Techne in Its US$11.3 Billion Acquisition by Merck KGaA sidley.com
- 25 Jun 2026 Press release (PR Newswire), Merck KGaA, Darmstadt, Germany, Agrees to Acquire Bio-Techne, Strengthening Leadership Position in Fast-Growing Life Sciences Markets prnewswire.com
- 20 Aug 2026 Definitive merger proxy statement (DEFM14A), BIO-TECHNE Corp sec.gov



